These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37990228)

  • 21. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
    Wei S; Song J; Xie Y; Huang J; Yang J
    JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
    Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
    Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation.
    Ye J; Zhuang X; Li X; Gong X; Sun Y; Wang W; Feng S; Wu T; Zhong B
    Metabolism; 2022 Nov; 136():155294. PubMed ID: 35995280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: Results from two prospective cohorts.
    Zhang Y; Zhang T; Liu Y; Bai S; Jiang J; Zhou H; Luan J; Cao L; Lv Y; Zhang Q; Liu L; Sun S; Wang X; Zhou M; Jia Q; Song K; Zhang H; Chang Q; Fan X; Ding Y; Chen L; Zhao Y; Niu K; Xia Y
    Diabetes Metab Syndr; 2023 Oct; 17(10):102873. PubMed ID: 37804689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age at menarche and metabolic dysfunction-associated fatty liver disease: Evidence from a large population-based epidemiological study in Southwest China.
    Li K; Yin J; Qin Z; Ma B; He R; Zhuoma D; Wang Z; Liu Q; Zhao X
    Prev Med; 2023 Dec; 177():107776. PubMed ID: 37951543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
    Liu Q; Zhao G; Li Q; Wu W; Zhang Y; Bian H
    BMC Gastroenterol; 2022 Nov; 22(1):471. PubMed ID: 36402947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study.
    Farrell AM; Magliano DJ; Shaw JE; Thompson AJ; Croagh C; Ryan MC; Howell J
    Sci Rep; 2022 Feb; 12(1):1956. PubMed ID: 35121749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clustering of lifestyle characteristics and their association with cardio-metabolic health: the Lifestyles and Endothelial Dysfunction (EVIDENT) study.
    Patino-Alonso MC; Recio-Rodríguez JI; Magdalena-Belio JF; Giné-Garriga M; Martínez-Vizcaino V; Fernández-Alonso C; Arietaleanizbeaskoa MS; Galindo-Villardon MP; Gómez-Marcos MA; García-Ortiz L;
    Br J Nutr; 2015 Sep; 114(6):943-51. PubMed ID: 26268844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between complement C3 and the prevalence of metabolic-associated fatty liver disease in a Chinese population: a cross-sectional study.
    Feng L; Zhao Y; Wang WL
    BMJ Open; 2021 Oct; 11(10):e051218. PubMed ID: 34711595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China.
    Yuan Q; Wang H; Gao P; Chen W; Lv M; Bai S; Wu J
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study.
    Huang YP; Zhang S; Zhang M; Wang Y; Wang WH; Li J; Li C; Lin JN
    BMJ Open; 2021 Dec; 11(12):e056260. PubMed ID: 34911725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clustering of lifestyle and health behaviours in Australian adolescents and associations with obesity, self-rated health and quality of life.
    Ahmad K; Keramat SA; Ormsby GM; Kabir E; Khanam R
    BMC Public Health; 2023 May; 23(1):847. PubMed ID: 37165347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China.
    Wei JY; Xu Z; Li H; Du WQ; Niu BL; Li S; Tian S; Wu J; Chen YL; Li X; Liu ZL; Xiao J; Ren GS; Ran L; Kong LQ
    Int J Med Sci; 2021; 18(14):3082-3089. PubMed ID: 34400878
    [No Abstract]   [Full Text] [Related]  

  • 40. Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study.
    Lee GB; Huh Y; Lee SH; Han B; Kim YH; Kim DH; Kim SM; Choi YS; Cho KH; Nam GE
    World J Gastroenterol; 2023 Dec; 29(45):5962-5973. PubMed ID: 38131000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.